CoChat

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

Disselhorst, Maria J, Quispel-Janssen, Josine, Lalezari, Ferry, Monkhorst, Kim, de Vries, Jeltje F, van der Noort, Vincent, Harms, Emmy, Burgers, Sjaak, Baas, Paul · 2019 · The Lancet Respiratory Medicine

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Background Single-drug checkpoint inhibition has shown efficacy in patients with recurrent malignant pleural mesothelioma. Here, we assessed the safety and efficacy of the combination of nivolumab, an anti-programmed cell death 1 antibody, plus ipilimumab, an anti-cytotoxic T-lymphocyte protein 4 antibody, in patients with previously treated and relapsed malignant pleural mesothelioma.Methods INITIATE was a prospective single-centre, single arm, phase 2 trial. Patients with malignant pleural mesothelioma who progressed after at least one line of platinum-containing chemotherapy were enrolled. Key eligibility criteria were measurable disease according to the modified Response Evaluation Criteria in Solid Tumours for mesotheliomas, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received intravenous nivolumab (240 mg every 2 weeks) plus intravenous ipilimumab (1 mg/kg every 6 weeks up to four times). Treatment was continued for up to 2 years or until confirmed progression or unacceptable toxicity. The primary endpoint was disease control at 12 weeks. All patients who received at least one dose of therapy were included in safety analysis and all patients who received one dose of therapy and at least one radiological assessment were included in the primary analysis. This trial is registered at ClinicalTrials.gov, number NCT03048474.Findings Between Oct 5, 2016, and Aug 3, 2017, 38 patients were enrolled in the study, of which two patients were excluded because they were not eligible for a biopsy. Of 36 eligible patients, one deteriorated before the start of the study so was not included in any analyses and one withdrew consent after one treatment cycle before radiological assessment so was included in the safety population only. 34 patients were evaluable for response assessment at 12 weeks. Of these, ten (29%) patients had a partial response and 13 (38%) patients had stable disease; thus, disease control was achieved by 23 (68%, 95% CI 50-83) of 34 patients. Treatment-related adverse events were reported in 33 (94%) patients. The most common adverse events were infusion-related reactions, skin disorders, and fatigue. Grade 3 treatment-related adverse events were reported in 12 (34%) of 35 patients.Interpretation In this single-centre phase 2 trial, the combination of nivolumab plus ipilimumab showed marked efficacy in patients with recurrent malignant pleural mesothelioma. The safety profile was consistent with known data on the combination regimen. Our results warrant further investigation of this combination in a phase 3 trial.Funding Bristol-Myers Squibb.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(18)30420-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 250

Metadata

Authors
Disselhorst, M. J., Quispel-Janssen, J., Lalezari, F., Monkhorst, K., de Vries, J. F., van der Noort, V., Harms, E., Burgers, S., & Baas, P.
Affiliations
The Netherlands Cancer Institute (NL)
Corresponding author
Disselhorst, Maria J
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2019-03
Volume
7
Issue
3
Pages
260-270
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2908887190
Cited by
250
References
34
Citations by year
2026: 8 · 2025: 19 · 2024: 17 · 2023: 27 · 2022: 42 · 2021: 73 · 2020: 43 · 2019: 21
FWCI
32.88
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
malignant pleural mesothelioma, ipilimumab, nivolumab, immune checkpoint inhibitors, CTLA-4, PD-1, combination immunotherapy, disease control, treatment-related adverse events, immune-related adverse events, platinum-refractory disease, treatment efficacy and safety
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Mesothelioma, Malignant, Aged, Eligibility Determination, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Neoplasm Recurrence, Local, Pleural Neoplasms, Prospective Studies, Treatment Outcome, Drug Monitoring, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Administration, Intravenous, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30420-x
The paper
Disselhorst, M. J., Quispel-Janssen, J., Lalezari, F., Monkhorst, K., de Vries, J. F., van der Noort, V., Harms, E., Burgers, S., & Baas, P. (2019). Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30420-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.